268 related articles for article (PubMed ID: 12634968)
21. [A Case of Metastatic Seminomatous Testicular Tumor with Complicated Diagnosis by FDG-PET].
Hashizume A; Mizuno N; Kawai M; Kishida T
Hinyokika Kiyo; 2016 Jul; 62(7):383-7. PubMed ID: 27569358
[TBL] [Abstract][Full Text] [Related]
22. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
[TBL] [Abstract][Full Text] [Related]
23. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
24. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse.
Sanchez D; Zudaire JJ; Fernandez JM; Lopez J; Arocena J; Sanz G; Gimenez M; Rosell D; Robles JE; Berian JM
BJU Int; 2002 Jun; 89(9):912-6. PubMed ID: 12010239
[TBL] [Abstract][Full Text] [Related]
25. Tumor markers and
Dondi F; Albano D; Bertagna F; Giubbini R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):287-292. PubMed ID: 34425969
[TBL] [Abstract][Full Text] [Related]
26. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Decoene J; Winter C; Albers P
Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
[TBL] [Abstract][Full Text] [Related]
27. FDG PET for detection and therapy control of metastatic germ cell tumor.
Cremerius U; Effert PJ; Adam G; Sabri O; Zimmy M; Wagenknecht G; Jakse G; Buell U
J Nucl Med; 1998 May; 39(5):815-22. PubMed ID: 9591582
[TBL] [Abstract][Full Text] [Related]
28. The role of
Hung TJ; McLean L; Mitchell C; Pascoe C; Lawrentschuk N; Murphy DG; Iravani A; Singh D; Hofman MS; Zidan L; Akhurst T; Lewin J; Hicks RJ
Cancer Imaging; 2019 May; 19(1):28. PubMed ID: 31142361
[TBL] [Abstract][Full Text] [Related]
29. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
30. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
Guay C; Lépine M; Verreault J; Bénard F
J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
[TBL] [Abstract][Full Text] [Related]
32. [Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours].
Büchler T; Simonová K; Fencl P; Abrahámová J
Klin Onkol; 2011; 24(6):413-7. PubMed ID: 22257229
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
[TBL] [Abstract][Full Text] [Related]
34. [Positron emission tomography. Introduction of a new procedure in diagnosis of urologic tumors and initial clinical results].
Bachor R; Kocher F; Gropengiesser F; Reske SN; Hautmann RE
Urologe A; 1995 Mar; 34(2):138-42. PubMed ID: 7754585
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
36. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
37. PET in testicular cancer.
Becherer A
Methods Mol Biol; 2011; 727():225-41. PubMed ID: 21331937
[TBL] [Abstract][Full Text] [Related]
38. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
De La Pena H; Sharma A; Glicksman C; Joseph J; Subesinghe M; Traill Z; Verrill C; Sullivan M; Redgwell J; Bataillard E; Pintus E; Dallas N; Gogbashian A; Tuthill M; Protheroe A; Hall M
Eur J Cancer; 2017 Oct; 84():354-359. PubMed ID: 28866371
[TBL] [Abstract][Full Text] [Related]
39. [Positron emission tomography in germ cell tumors in men : Possibilities and limitations].
Schriefer P; Hartmann M; Oechsle K; Meyer CP; Klutmann S; Fisch M; Bokemeyer C; Oing C
Urologe A; 2019 Apr; 58(4):418-423. PubMed ID: 30374517
[TBL] [Abstract][Full Text] [Related]
40. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]